|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
09-17-2010, 01:48 AM
|
|||
|
|||
Commencement Of A Phase II Clinical Trial Of SG2000 In Ovarian Cancer
Spirogen Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic Therapeutics") announced the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is being sponsored by the National Cancer Institute (NCI) of the USA, and is now actively recruiting patients for treatment. The open-label Phase II study will evaluate the overall response rate of SG2000 in ...
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Synta expands STA-9090 Phase 2 clinical trial in NSCLC | cancerfr | AIDS-related cancer | 0 | 10-05-2010 03:07 AM |
| Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer | cancerfr | Ovarian Cancer | 0 | 09-15-2010 08:26 PM |
| Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with | cancerfr | Pancreatic Cancer | 0 | 07-01-2010 07:45 PM |
| FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer | cancerfr | Pancreatic Cancer | 0 | 05-03-2010 06:10 PM |
| OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva | cancerfr | Oral Cancer | 0 | 04-26-2010 02:19 PM |
Linear Mode
